Related Experiment Video
Updated: Feb 4, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal
Michael B Boffa1, Saverio Stranges2, Neil Klar3
1Department of Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada.
Insights
Elevated lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease. Research on Lp(a) in patients with existing heart disease shows inconsistent results, possibly due to index event bias.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Atherosclerosis Research
Background:
- Elevated lipoprotein(a) [Lp(a)] is an established risk factor for atherothrombotic diseases, primarily based on studies of first events.
- Inconsistent findings exist regarding Lp(a)'s impact on secondary atherothrombotic events in patients with pre-existing cardiovascular disease (CVD).
- This is critical as secondary prevention populations are targets for Lp(a) screening and emerging Lp(a)-lowering therapies.
Purpose of the Study:
- To review the secondary prevention literature concerning lipoprotein(a) [Lp(a)].
- To identify potential confounding factors contributing to inconsistent findings in this population.
- To address the clinical significance of Lp(a) in patients with established CVD.
Main Methods:
- Systematic review of published literature on Lp(a) and secondary atherothrombotic events.
- Analysis of studies investigating Lp(a) levels in patients with pre-existing cardiovascular disease.
- Exploration of potential biases, including index event bias, in the existing research.
Main Results:
- The literature presents conflicting data on the role of elevated Lp(a) in predicting recurrent atherothrombotic events.
- Index event bias is highlighted as a significant confounding factor potentially explaining discrepancies.
- Further research is needed to clarify Lp(a)'s precise role in secondary cardiovascular prevention.
Conclusions:
- The impact of elevated lipoprotein(a) [Lp(a)] on secondary atherothrombotic events requires further clarification.
- Index event bias may confound current understanding of Lp(a) in secondary prevention.
- Accurate assessment of Lp(a)'s risk in patients with established CVD is crucial for guiding future therapeutic strategies.
Abstract:
Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are an independent, and possibly causal, risk factor for atherothrombotic diseases including coronary heart disease. The principal evidence base for this comes from large population studies focusing on first atherothrombotic events. However, inconsistent findings have been reported from studies investigating the impact of elevated Lp(a) on atherothrombotic events in subjects with preexisting cardiovascular disease. This question is very important because the secondary prevention population is recommended for Lp(a) screening by some guidelines and could be an important target group for Lp(a)-lowering therapies that are currently on the horizon. In this review, we survey the secondary prevention literature as it relates to Lp(a) and identify some possible confounding factors that may underlie the inconsistent findings, such as index event bias.
Related Concept Videos
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Lazarus's Cognitive Appraisal Theory
Primary Appraisal:...
Secondary Active Transport
Secondary Healthcare System
Critical Region, Critical Values and Significance Level
In hypothesis testing, a sample statistic is converted to a test statistic using z, t, or chi-square distribution. A critical region is an area under the curve in probability distributions demarcated by the critical value. When the test statistic falls in this region, it suggests that the null hypothesis must be rejected. As this region contains all those values of the...
Critical Values

